ECSP24004256A - Composiciones que contienen adenosín trifosfato (atp) y métodos de uso para la función cognitiva - Google Patents
Composiciones que contienen adenosín trifosfato (atp) y métodos de uso para la función cognitivaInfo
- Publication number
- ECSP24004256A ECSP24004256A ECSENADI20244256A ECDI202404256A ECSP24004256A EC SP24004256 A ECSP24004256 A EC SP24004256A EC SENADI20244256 A ECSENADI20244256 A EC SENADI20244256A EC DI202404256 A ECDI202404256 A EC DI202404256A EC SP24004256 A ECSP24004256 A EC SP24004256A
- Authority
- EC
- Ecuador
- Prior art keywords
- atp
- methods
- cognitive function
- compositions containing
- adenosine triphosphate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000003920 cognitive function Effects 0.000 title abstract 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 title 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 title 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 abstract 2
- 229960001456 adenosine triphosphate Drugs 0.000 abstract 2
- 230000036997 mental performance Effects 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 230000002232 neuromuscular Effects 0.000 abstract 1
- 230000035484 reaction time Effects 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163213378P | 2021-06-22 | 2021-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP24004256A true ECSP24004256A (es) | 2024-02-29 |
Family
ID=84544774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI20244256A ECSP24004256A (es) | 2021-06-22 | 2024-01-19 | Composiciones que contienen adenosín trifosfato (atp) y métodos de uso para la función cognitiva |
Country Status (12)
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000095695A (ja) * | 1998-07-23 | 2000-04-04 | Nippon Koutai Kenkyusho:Kk | 精神分裂病治療薬 |
| US20030069203A1 (en) * | 2001-06-04 | 2003-04-10 | Lee Steve S. | Method for increasing human performance by reducing muscle fatigue and recovery time through oral administration of adenosine triphosphate |
| US7629329B2 (en) * | 2001-06-04 | 2009-12-08 | Tsi Health Sciences, Inc. | Method for increasing muscle mass and strength through administration of adenosine triphosphate |
| US20050261239A1 (en) * | 2004-05-23 | 2005-11-24 | Universiteit Van Maastricht | Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue |
| KR101424833B1 (ko) * | 2006-06-27 | 2014-08-01 | 코와 가부시키가이샤 | 피로 예방 및/또는 회복을 위한 의약 |
| US9522161B2 (en) * | 2010-10-26 | 2016-12-20 | Advanced Bio Development, Inc. | Performance enhancing composition and method of delivering nutrients |
| CN113142581B (zh) * | 2010-12-23 | 2025-07-22 | 阿马曾提斯公司 | 用于改善线粒体功能的组合物和方法 |
| US20140044690A1 (en) * | 2012-08-08 | 2014-02-13 | University Of South Florida | High-Energy Compounds for Use in Alzheimer's and Other Neurodegenerative Diseases |
| BR112015005199B1 (pt) * | 2012-09-10 | 2022-09-06 | Metabolic Technologies, Inc | Composição, e, método para fornecer um benefício a um animal em necessidade do mesmo |
| WO2014106860A2 (en) * | 2013-01-03 | 2014-07-10 | Laila Nutraceuticals | Synergistic dietary supplement compositions for enhancing physical performance and energy levels |
| US10888576B2 (en) * | 2018-10-08 | 2021-01-12 | Metabolic Technologies, Inc. | Composition of HMB and ATP and methods of use |
| WO2021046357A1 (en) * | 2019-09-05 | 2021-03-11 | Jiangyin Tsi Pharmaceutical Co., Ltd. | Compositions containing adenosine triphosphate (atp) and methods of use |
-
2022
- 2022-06-22 JP JP2023579443A patent/JP2024524288A/ja active Pending
- 2022-06-22 AU AU2022297444A patent/AU2022297444A1/en active Pending
- 2022-06-22 EP EP22829221.5A patent/EP4358972A4/en active Pending
- 2022-06-22 CN CN202280056829.6A patent/CN117835985A/zh active Pending
- 2022-06-22 US US18/573,609 patent/US20240299435A1/en active Pending
- 2022-06-22 PE PE2023003445A patent/PE20241617A1/es unknown
- 2022-06-22 MX MX2024000145A patent/MX2024000145A/es unknown
- 2022-06-22 CA CA3224861A patent/CA3224861A1/en active Pending
- 2022-06-22 WO PCT/US2022/034510 patent/WO2022271813A1/en not_active Ceased
-
2023
- 2023-12-22 CL CL2023003882A patent/CL2023003882A1/es unknown
-
2024
- 2024-01-19 EC ECSENADI20244256A patent/ECSP24004256A/es unknown
- 2024-01-22 CO CONC2024/0000517A patent/CO2024000517A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20241617A1 (es) | 2024-08-07 |
| CA3224861A1 (en) | 2022-12-29 |
| CN117835985A (zh) | 2024-04-05 |
| CO2024000517A2 (es) | 2024-05-10 |
| AU2022297444A1 (en) | 2024-01-18 |
| US20240299435A1 (en) | 2024-09-12 |
| EP4358972A4 (en) | 2025-04-16 |
| EP4358972A1 (en) | 2024-05-01 |
| WO2022271813A1 (en) | 2022-12-29 |
| CL2023003882A1 (es) | 2024-07-05 |
| MX2024000145A (es) | 2024-03-22 |
| JP2024524288A (ja) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023014770A2 (es) | Degradadores de cdk2 y sus usos | |
| CO2025009073A2 (es) | Compuestos cíclicos fusionados y uso de los mismos | |
| CO2022001210A2 (es) | Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes | |
| CO2023014622A2 (es) | Conjugados de anticuerpo-fármaco anti-c-met | |
| MX2021009259A (es) | Conjugados de il-2 y metodos de uso del mismo. | |
| CO2023010562A2 (es) | Degradadores irak4 y usos de los mismos | |
| CR8402A (es) | Indazol-o-glucosidos sustitutos | |
| MX2022001776A (es) | Terapias de combinacion de inmuno oncologia con conjugados de il-2. | |
| PE20220017A1 (es) | Inhibidores del kcnt1 y metodos de uso | |
| GT201000061A (es) | Derivados de uracilo o timina para el tratamiento de hepatitis c | |
| PA8608901A1 (es) | Derivados de piperazina | |
| CO2024001102A2 (es) | Compuestos de pirazolopiridinona | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| CL2021001753A1 (es) | Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253). | |
| CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
| CR20220418A (es) | Compuestos tetracíclicos para el tratamiento de infecciones por vih | |
| DOP2022000015A (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos | |
| PA8577201A1 (es) | 3-fenil-propionamido, 3-fenil-acrilamido y derivados 3-fenil-propinamido como inhibidores de mao-b | |
| CO2025009897A2 (es) | Degradadores de irak y usos de los mismos | |
| PY2201650A (es) | Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos | |
| UY39061A (es) | Inhibidores macrocíclicos de rip2-cinasa | |
| CL2025002072A1 (es) | Inhibidores de prmt5–mta. | |
| CL2004001349A1 (es) | Compuestos derivados de pirazoloirimidinas; procedimiento de obtencion; compuestos intermediarios; agentes fungicidas que los contienen utiles para combatir hongos nocivos. | |
| CL2023003951A1 (es) | Inhibidores de transglutaminasas | |
| AR033702A1 (es) | Compuestos triciclicos utiles como inhibidores de la transcriptasa inversa del vih |